Evotec and Shire Team Up to Tackle Fabry’s Disease

In Partnering & Investment by Cecile

The Two Pharmaceutical Companies Have Teamed Up to Develop Drugs Against Fabry’s Disease

The German pharmaceutical company Evotec is developing small molecules inhibitors to treat Fabry’s disease, which is an inherited disorder of lysosomal storage. The company will team up with Shire for a period of three years to share drug discovery technologies, particularly Shire’s computational chemistry platforms and high-throughput sequencing.

The deal was announced earlier this week when Shire announced its first half of 2014 financial results.

Shire has developed and marketed a number of treatments for rare diseases and has extensive expertise in the field. Increasingly, large pharmaceutical companies are looking into investing an research into rare diseases. In the partnership, Evotec is offering up its discovery and development platforms.